Acutaas Chemicals Ltd (NSE: ACUTAAS) and Ipca Laboratories Ltd. (NSE: IPCALAB) are both listed in the Medicinal Chemicals and Botanical Products industry. Acutaas Chemicals has a market capitalisation of ₹31,869 Cr and Ipca Laboratories ₹49,470 Cr, as of 9 Nov 2026. Their P/E ratios are 89.8 and 43.4 respectively. Return on equity is 23.52% for Acutaas Chemicals and 13.22% for Ipca Laboratories. Over one year, Acutaas Chemicals's share price is up 113.6% and Ipca Laboratories's is up 54.2%.
| Metric | Acutaas Chemicals | Ipca Laboratories |
|---|---|---|
| NSE Symbol | ACUTAAS | IPCALAB |
| BSE Code | 543349 | 524494 |
| Share Price | ₹3,866.60 | ₹1,960.00 |
| Market Cap | ₹31,869 Cr | ₹49,470 Cr |
| P/E Ratio | 89.8 | 43.4 |
| Return on Equity | 23.52% | 13.22% |
| Return on Assets | 15.74% | 8.42% |
| Dividend Yield | 0.06% | 0.31% |
| Beta (1Y) | 0.23 | -0.04 |
| 1-Year Price Change | +113.6% | +54.2% |
| 3-Month Price Change | +17.8% | +16.3% |
| 52-Week Range | ₹1,570.00 – ₹4,045.30 | ₹1,293.90 – ₹2,038.00 |
| Latest Quarter | Q2 FY27 | Q2 FY27 |
| Quarterly Revenue | ₹437 Cr | ₹2,910 Cr |
| Quarterly Net Profit | ₹123 Cr | ₹389 Cr |
| Net Margin | 28.2% | 13.4% |
| EPS (Basic, Quarter) | ₹15.29 | ₹14.79 |
| Results Basis | consolidated | consolidated |
| Headquarters | Surat, Gujarat | Mumbai, Maharashtra |
The figures sit side by side and are not ranked. Quarterly figures are in ₹ crore, parsed from each company's exchange filing (XBRL); the two companies' latest quarters can differ.
Acutaas Chemicals Limited engages in the research and development, manufacture, and sale of pharmaceutical intermediates in India and internationally. The company offers pharma intermediates for use in regulated and generic active pharmaceutical ingredients for anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson’s, antidepressant, and anticoagulant applications. It also provides specialty chemicals for use in battery chemicals, personal care, agrochemicals, coatings, electronics, and industrial processes; photoresist chemicals to semiconductor applications; electrol…
Ipca Laboratories Limited, an integrated pharmaceutical company, manufactures and markets formulations and active pharmaceutical ingredients (APIs) for various therapeutic segments in India, Europe, Africa, the Americas, Asia, the Commonwealth of Independent States, and Australasia. The company offers APIs in anti-hypertensive, anti-malarial, diuretic, DMARD, anti-hypertensive, and anthelmintic therapeutic areas. It also provides generic and branded formulations in various therapeutic segments, including allergy, anti-neoplastic/cancer drugs, anti-arthritic, anti-epileptic, anti-hypertensive, …
Ipca Laboratories has a market capitalisation of ₹49,470 Cr, against ₹31,869 Cr for Acutaas Chemicals as of 9 Nov 2026, about 1.6 times the size by market cap.
Acutaas Chemicals has a P/E of 89.8 and Ipca Laboratories a P/E of 43.4 as of 9 Nov 2026.
Acutaas Chemicals has a return on equity of 23.52% and Ipca Laboratories 13.22%.
Acutaas Chemicals's share price is up 113.6% over one year and Ipca Laboratories's is up 54.2%.
Acutaas Chemicals reported revenue of ₹437 Cr and net profit of ₹123 Cr for Q2 FY27. Ipca Laboratories reported revenue of ₹2,910 Cr and net profit of ₹389 Cr for Q2 FY27. Figures are parsed from each company's exchange filing.
Both are classified under Pharmaceuticals > Biotechnology and Life Sciences > Medicinal Chemicals and Botanical Products on FinBizNet.
No. The page lays the two companies' published figures side by side and draws no conclusion from them. It is descriptive market data, not investment advice.
Data as of 9 Nov 2026. Descriptive market data only — not investment advice.